Immunomedics (NASDAQ:IMMU) “Buy” Rating Has Just Been Reiterated by Wells Fargo

May 18, 2018 - By Kristen Paramore

Immunomedics, Inc. (NASDAQ:IMMU) Logo

Investors sentiment decreased to 1.07 in 2017 Q4. Its down 0.58, from 1.65 in 2017Q3. It worsened, as 27 investors sold Immunomedics, Inc. shares while 44 reduced holdings. 29 funds opened positions while 47 raised stakes. 117.18 million shares or 4.91% more from 111.69 million shares in 2017Q3 were reported.

Next Group Inc holds 0.84% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 121,350 shares. Axiom Int Limited Com De has invested 0.05% in Immunomedics, Inc. (NASDAQ:IMMU). Ny State Common Retirement Fund reported 0% stake. Prudential Fin holds 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 10,983 shares. Legal And General Public Limited Company accumulated 26,088 shares. Nea Management Communication Ltd Limited Liability Company reported 1.86% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Northern Corp has invested 0.01% in Immunomedics, Inc. (NASDAQ:IMMU). Gotham Asset Management Ltd Llc holds 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 13,364 shares. Moreover, Fred Alger Mngmt has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 55,000 shares. Proshare Advisors Ltd owns 97,075 shares or 0.01% of their US portfolio. Creative Planning has 0.01% invested in Immunomedics, Inc. (NASDAQ:IMMU). American Grp accumulated 68,857 shares or 0% of the stock. Ghost Tree Cap Limited Co holds 5.83% in Immunomedics, Inc. (NASDAQ:IMMU) or 1.54 million shares. Royal Bancshares Of Canada reported 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Swiss Fincl Bank accumulated 156,650 shares.

Since February 28, 2018, it had 0 insider purchases, and 1 sale for $2.05 million activity.

Immunomedics (NASDAQ:IMMU) Rating Reaffirmed

Immunomedics (NASDAQ:IMMU) has had their stock rating noted as a solid “Buy” by research analysts at Wells Fargo. This was disclosed to clients in analysts note on Thursday, 17 May.

Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage

Among 2 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Immunomedics had 2 analyst reports since December 6, 2017 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Wednesday, December 6. The firm earned “Buy” rating on Wednesday, December 6 by Cowen & Co.

The stock increased 7.12% or $1.39 during the last trading session, reaching $20.9. About 8.09 million shares traded or 326.88% up from the average. Immunomedics, Inc. (NASDAQ:IMMU) has risen 117.70% since May 18, 2017 and is uptrending. It has outperformed by 106.15% the S&P500.

Analysts await Immunomedics, Inc. (NASDAQ:IMMU) to report earnings on August, 15. They expect $-0.15 earnings per share, up 40.00 % or $0.10 from last year’s $-0.25 per share. After $-0.14 actual earnings per share reported by Immunomedics, Inc. for the previous quarter, Wall Street now forecasts 7.14 % negative EPS growth.

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company has market cap of $3.50 billion. The firm engages in developing antibody-drug conjugate products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It currently has negative earnings. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody.

More important recent Immunomedics, Inc. (NASDAQ:IMMU) news were published by: which released: “Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast …” on May 16, 2018, also published article titled: “Reader Inquiry: Is There Further Upside In Immunomedics?”, published: “Immunomedics’ (IMMU) option implied volatility into ASCO” on May 17, 2018. More interesting news about Immunomedics, Inc. (NASDAQ:IMMU) was released by: and their article: “Pre-Open Movers 05/17: (WWE) (LOXO) (NTES) Higher; (JNCE) (JCP) (ACXM) Lower (more…)” with publication date: May 17, 2018.

Immunomedics, Inc. (NASDAQ:IMMU) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: